BOONE, THOMAS C.,OLINER, JONATHAN D.,LEE, EUNKYUNG,BOONE, Thomas C.,OLINER, Jonathan D.,LEE, Eunkyung
申请号：
RSP20140162
公开号：
RS53262B
申请日:
2009.02.20
申请国别(地区):
RS
年份:
2014
代理人:
摘要：
Crystalline hydrochloride salt of (5-{(R)-2-[3-(4,4-diethyl-2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-1,1-dimethylpropylamino]-1-hydroxy-ethyl}-2-hydroxyphenyl)-methane sulfonamide (I), is new. Independent claims are included for: (1) a medicament combination comprising (I) and further active agent of one or more other compounds, which are anticholinergics, corticosteroids, phosphodiesterase 4-inhibitors, leukotriene D4 antagonists, epidermal growth factor receptor inhibitors, dopamine-agonists, H1-antihistamines and/or phosphatidylinositol 3-kinase inhibitors； and (2) preparing an inhalation solution comprising dissolving the active agent of (I). ACTIVITY : Respiratory-Gen.； CNS-Gen.； Antiinflammatory； Antiasthmatic； Cytostatic； Antimicrobial； Virucide； Antibacterial； Fungicide； Protozoacide； Anthelmintic； Dermatological； Immunosuppressive. MECHANISM OF ACTION : None given.Izolovano antitelo ili njegov antigen-vezujući fragment, naznačen time, što sadrži varijabilni domen teškog lanca i varijabilni domen lakog lanca sa sekvencama odabranim iz grupe koja se sastoji od:(a) SEQ ID NO: 4 i SEQ ID NO: 12；(b) SEQ ID NO: 7 i SEQ ID NO: 12；(c) SEQ ID NO: 3 i SEQ ID NO: 17；(d) SEQ ID NO: 6 i SEQ ID NO: 12；(e) SEQ ID NO: 5 i SEQ ID NO: 12；(f) SEQ ID NO: 3 i SEQ ID NO: 12；(g) SEQ ID NO: 7 i SEQ ID NO: 11；(h) SEQ ID NO: 1 i SEQ ID NO: 12；(i) SEQ ID NO: 7 i SEQ ID NO: 13；(j) SEQ ID NO: 4 i SEQ ID NO: 13；(k) SEQ ID NO: 2 i SEQ ID NO: 12；(1) SEQ ID NO: 7 i SEQ ID NO: 10；(m) SEQ ID NO: 3 i SEQ ID NO: 16；(n) SEQ ID NO: 4 i SEQ ID NO: 11；(o) SEQ ID NO: 3 i SEQ ID NO: 9；(p) SEQ ID NO: 3 i SEQ ID NO: 11；(q) SEQ ID NO: 3 i SEQ ID NO: 10；(r) SEQ ID NO: 7 i SEQ ID NO: 15；(s) SEQ ID NO: 7 i SEQ ID NO: 8；(t) SEQ ID NO: 3 i SEQ ID NO: 15；(u) SEQ ID NO: 7 i SEQ ID NO: 16； i(v) SEQ ID NO: 7 i SEQ ID NO: 14；pri čemu se pomenuto antitelo ili njegov antigen-vezujući fragment specifično vezuje za najmanje jedan od Ang-1 i Ang-2 liganda Tie-2 receptora.Prijava sadrži još 18 patentnih zahteva.
